Browse Biological products topic

Product development subtopic

Articles 1-27 out of 27 article(s) Title Author Type Date Words United States : Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design. Nov 17, 2009 422 Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design. Nov 17, 2009 1037 Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System. Nov 16, 2009 152 MD Biosciences has created a new division, MD Bioproducts, to develop high quality research products. Nov 1, 2009 58 AdvanSource Biomaterials Announces Multi-Year Development Agreement. Aug 19, 2009 460 Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma. Jun 18, 2009 862 Xencor Presents Preliminary Phase I Data on XmAb[R]2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting. Jun 1, 2009 751 HemCon Medical Technologies Inc. and ProMetic BioSciences Ltd. Announce Collaborative Development Agreement. Mar 3, 2009 843 Biothera Expands Metastatic Colorectal Cancer Trial. Jan 29, 2009 458 Goodwin Biotechnology, Inc. Completes GMP Manufacturing of Neogenix Oncology, Inc. Monoclonal Antibody for Upcoming Clinical Trials. Jan 28, 2009 534 Biothera Completes Enrollment of First Arm of Metastatic Colorectal Cancer Trial. Oct 7, 2008 364 Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer. Sep 8, 2008 1689 La Jolla Pharmaceutical Announces Positive 12-Month Interim Antibody Data and Provides Update for Ongoing Riquent(R) Phase 3 'ASPEN' Lupus Trial. Clinical report Apr 23, 2008 2169 Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial. Mar 28, 2008 777 Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma. Feb 11, 2008 490 Panacea announces selection of PAN-622 - a fully human sequence monoclonal antibody against HAAH - as its lead cancer therapeutic product. Nov 1, 2007 793 KaloBios Initiates a U.S. Phase 1 Study of Its Second Drug Candidate, KB001. Jun 11, 2007 384 Pieris progresses development of its proprietary biotherapeutics platform. Jun 1, 2007 534 Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation. Mar 12, 2007 898 Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation. Mar 12, 2007 913 Seattle Genetics Initiates Phase I Clinical Trial of SGN-35. Nov 17, 2006 681 Consider the Integration of Pharmacokinetic & Pharmacodynamic Concepts into the Biotech Drug Development Plan. Oct 17, 2006 695 Caprion Receives FDA Fast Track Designation for Shigamabs Clinical Program. May 10, 2006 708 Seattle Genetics and Laureate Pharma Announce Manufacturing Agreement. Apr 25, 2006 892 Aphton Announces Closing of Commercialization and Manufacturing Agreements for IGN311 With Celltrion. Nov 17, 2005 801 Novel enzyme infusion technique uses positive pressure. Nov 1, 2005 315 Northwestern obtains United States patent. Brief Article Apr 1, 2005 133